

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI140599

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
JPMORGAN CHASE BANK, N.A., as administrative agent	04/02/2024
RECEIVING PARTY DATA	
Company Name:	PELVALON, INC.
Street Address:	923 THOMPSON PLACE
City:	SUNNYVALE
State/Country:	CALIFORNIA
Postal Code:	94085
PROPERTY NUMBERS Total: 8	
Property Type	Number
Application Number:	13635598
Application Number:	13625683
Application Number:	13679484
Application Number:	13679528
Application Number:	14293365
Application Number:	16838452
Application Number:	14181576
Application Number:	15631641
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3127018637
Email:	ipdocket@mayerbrown.com,wsiegel@mayerbrown.com
Correspondent Name:	William R. Siegel
Address Line 1:	71 S. Wacker Drive
Address Line 2:	42-62
Address Line 4:	Chicago, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	24762301
NAME OF SUBMITTER:	William Siegel
SIGNATURE:	William Siegel

PATENT

DATE SIGNED:	04/03/2024
Total Attachments: 5 source=Laborie - Release of Patent Security Agreement (Pelvalon, Inc.) (EV)#page1.tif source=Laborie - Release of Patent Security Agreement (Pelvalon, Inc.) (EV)#page2.tif source=Laborie - Release of Patent Security Agreement (Pelvalon, Inc.) (EV)#page3.tif source=Laborie - Release of Patent Security Agreement (Pelvalon, Inc.) (EV)#page4.tif source=Laborie - Release of Patent Security Agreement (Pelvalon, Inc.) (EV)#page5.tif	

Termination and Release of Patent Security Agreement

This Termination and Release of Patent Security Agreement is executed as of April 2, 2024 (this "**Release**"), by JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity the "**Administrative Agent**"), for the benefit of PELVALON, INC. (the "**Grantor**").

WITNESSETH:

Whereas, reference is made to the Credit Agreement dated as of February 12, 2020 (as amended by Amendment and Waiver No. 1, dated as of November 18, 2020, Amendment No. 2 to Credit Agreement, dated as of January 7, 2022, Amendment No. 3 to Credit Agreement, dated as of June 27, 2023, and as further amended, restated, amended and restated, extended, supplemented or otherwise modified from time to time, the "**Credit Agreement**"), among LMT GROUP HOLDINGS CORP., a Delaware corporation ("**Holdings**"), LABORIE MEDICAL TECHNOLOGIES CORP., a Delaware corporation (the "**US Borrower**"), Laborie Medical Technologies Canada ULC, an unlimited liability company incorporated under the laws of British Columbia (the "**Canadian Borrower**"), Medical Measurement Systems B.V., a private limited liability company (*besloten vennootschap met beperkte aansprakelijkheid*) having its official seat (*statutaire zetel*) in Enschede, the Netherlands, registered with the Dutch trade register under number 06070224 (the "**Dutch Borrower**" and, together with the U.S. Borrower and the Canadian Borrower, collectively, the "**Borrowers**" and each a "**Borrower**"), the Lenders and the Issuing Banks from time to time party thereto and JPMorgan, as Administrative Agent.

Whereas, the Grantor is a party to a Collateral Agreement dated as of February 12, 2020 (as supplemented by Supplement No. 1, dated as of November 6, 2020, as supplemented by Supplement No. 2, dated as of November 12, 2021, as supplemented by Supplement No. 3, dated as of June 8, 2022 and as supplemented by Supplement No. 4, dated as of December 8, 2023, the "**Collateral Agreement**"), pursuant to which the Grantor executed and delivered that certain Patent Security Agreement dated as of November 12, 2021 (the "**Patent Security Agreement**"; any capitalized term used but not otherwise defined herein shall have the meaning assigned to such term in the Patent Security Agreement or the Collateral Agreement, as applicable) between the Grantor and the Administrative Agent.

Whereas, pursuant to the Patent Security Agreement, as security for the prompt and complete payment and performance, as the case may be, in full of the Secured Obligations (as defined in the Credit Agreement), the Grantor pursuant to the Collateral Agreement or applicable Security Document granted to the Administrative Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest in (the "**Security Interest**") all of the Grantor's right, title and interest in, to and under all **Patent Collateral** (as such term is defined in the Patent Security Agreement), including the Patent Collateral listed on Schedule 1 attached hereto.

Whereas, the Administrative Agent (acting on behalf of the Secured Parties) has agreed to release its Security Interest created under the Patent Security Agreement with respect to the Patent Collateral (as such term is defined in the Patent Security Agreement), including the Patent Collateral listed in Schedule 1 attached hereto, on the terms and conditions set forth in that certain Payoff Letter dated as of March 29, 2024, between the Administrative Agent, the Grantor and certain other parties thereto.

Now, therefore, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent (acting on behalf of the Secured Parties) hereby releases, cancels, terminates and discharges its Security Interest in the Patent Collateral (as that term is defined in the Patent Security Agreement), including

the Patent Collateral listed on Schedule 1 attached hereto, created by the Patent Security Agreement and the Collateral Agreement, as applicable, as of the date first written above and any right, title or interest of the Administrative Agent in the Patent Collateral (as that term is defined in the Patent Security Agreement), including the Patent Collateral listed on Schedule 1 attached hereto, created by the Patent Security Agreement or the Collateral Agreement, as applicable, shall hereby cease and become void. If and to the extent the Administrative Agent has acquired any right, title or interest under the Patent Security Agreement or the Collateral Agreement, as applicable, in the Patent Collateral (as that term is defined in the Patent Security Agreement), including the Patent Collateral listed on Schedule 1 attached hereto, the Administrative Agent hereby re-transfers, re-conveys, and re-assigns such right, title or interest to the Grantor.

The Administrative Agent hereby terminates and cancels the Patent Security Agreement.

The Administrative Agent hereby agrees, upon reasonable request and at the sole expense of the Grantor, to deliver such further documents and do such other acts as may be reasonably necessary to effectuate the release of the Security Interest in the Patent Collateral contemplated hereby.

This Release and the rights and obligations of the parties hereunder are governed by, and will be construed in accordance with, the internal laws of the State of New York (including, without limitation, Section 5-1401 of the General Obligations Law of the State of New York). This Release will be binding upon and inure to the benefit of each party and its successors and assigns.

[Signature page follows]

JPMORGAN CHASE BANK, N.A.,
as Administrative Agent

By: *A. Winkler*
Name: *Leah Winkler*
Title: *Authorized Officer*

[Signature Page to Termination and Release of Patent Security Agreements]

PATENT
REEL: 066989 FRAME: 0608

Schedule 1
Released Patents

U.S. Patents:

Title	Jurisdiction	Application No./ Filing Date	Patent No./ Issue Date	Owner
INTRA-VAGINAL DEVICE FOR FECAL INCONTINENCE	UNITED STATES	13/635,598	9,289,278	Pelvalon, Inc.
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL INCONTINENCE	UNITED STATES	13/625,683	8,740,766	Pelvalon, Inc.
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL	UNITED STATES	13/679,484	8,740,767	Pelvalon, Inc.
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL	UNITED STATES	13/679,528	9,707,067	Pelvalon, Inc.
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL	UNITED STATES	14/293,365	10,617,503	Pelvalon, Inc.
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL	UNITED STATES	16/838,452	9,974,635	Pelvalon, Inc.
INTRA-VAGINAL DEVICES AND METHODS OF TREATING FECAL	UNITED STATES	14/181,576	9,999,490	Pelvalon, Inc.

U.S. Patent Applications:

Title	Jurisdiction	Application No.	Patent No./ Issue Date	Owner
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL	U.S.	15/631,641	—	Pelvalon, Inc.

Canadian Patents:

Title	Jurisdiction	Application No.	Patent No.	Owner
INTRA-VAGINAL DEVICES AND METHODS FOR TREATING FECAL INCONTINENCE	CANADA	2849734	2011227265	Pelvalon, Inc.

INTRA-VAGINAL DEVICE FOR FECAL INCONTINENCE	CANADA	2793488	2547284	Pelvalon, Inc.
---	--------	---------	---------	----------------